WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

NCT ID: NCT06106152

Last Updated: 2024-03-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-05
• Study Completion Date: 2025-12-31

Brief Summary

This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer

Detailed Description

The trial consist of Screening Period (30 days), Treatment Period (21*n days), Safety Follow-up Period (90 days) and Survival follow-up.

About 20 subjects are planned to be enrolled in the study.

Conditions

Advanced Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fixed-dose in patients with advanced lung cancer

WTX212A injection Fixed-dose in advanced lung cancer patients

Group Type: EXPERIMENTAL

WTX212A injection

Intervention Type: DRUG

The WTX212A infusion is given every 21 days

Combined Study in patients with advanced lung cancer

Fixed-dose WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer

Group Type: EXPERIMENTAL

WTX212A injection

Intervention Type: DRUG

The WTX212A infusion is given every 21 days

PD -1/PD-L1 monoclonal antibody

Intervention Type: DRUG

The PD -1/PD-L1 monoclonal antibody is given every 21 days

Interventions

WTX212A injection

The WTX212A infusion is given every 21 days

Intervention Type: DRUG

PD -1/PD-L1 monoclonal antibody

The PD -1/PD-L1 monoclonal antibody is given every 21 days

Intervention Type: DRUG

Other Intervention Names

autologous red blood cell PD-1 inhibitor conjugate; PD -1/PD-L1antibody

Eligibility Criteria

Inclusion Criteria

• The subject signs an informed consent form, understands this study, is willing to follow and has the ability to complete all experimental procedures;
• Regardless of gender, aged 18 to 75 years old (including threshold);
• Histologically or cytologically confirmed locally advanced (stage IIB/IIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) with disease progression or intolerance after treatment or extensive stage small cell Lung cancer (SCLC)
• Patients with lung cancer who have been treated with at least 1 line system therapy or cannot currently receive standard therapy, and who have been treated with PD-1 or PD-L1 inhibitor antibody in the terminal line therapy regimen for ≥ 2 cycles;
• ECOG ≤1
• Expected life ≥ 3 months；
• Male participants, their spouses, and female participants of childbearing age should agree to use a medically recognized effective contraceptive method from the signing of the informed consent form until 3 months after the last administration;

Exclusion Criteria

• People with other serious medical diseases, including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc., and people with uncontrollable or serious cardiovascular diseases,
• Patients with clinical symptoms and the need for repeated drainage of pleural and ascitic fluids;
• Previous or recent history of pulmonary fibrosis, severe lung function damage caused by pneumoconiosis, radiation pneumonia, and drug-related pneumonia;
• There have been adverse events related to the use of IO drugs that require permanent cessation of IO treatment;
• Known to have other malignant tumors, currently progressing or completing treatment at least once in the past 3 years. Exceptions include early tumors that have received radical treatment (carcinoma in situ or grade 1 tumor, non ulcerative primary melanoma with a depth of less than 1mm and no lymph nodes involved), skin basal cell carcinoma, skin squamous cell carcinoma, cervical carcinoma in situ, or breast carcinoma in situ that has received potential radical treatment;
• Subjects with symptomatic central nervous system (CNS) metastasis confirmed by imaging or pathological examination and clinically unstable for at least 14 days prior to enrollment who require steroid treatment;
• Having hereditary bleeding tendencies or coagulation disorders, or a history of thrombosis, hemolysis, or hemorrhagic diseases;
• Received significant surgical treatment or obvious traumatic injury within 28 days prior to the start of research treatment;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Westlake Therapeutics

INDUSTRY

Sponsor Role: collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Pingli Wang

Chief of Respiratory and Critical Care Medicine Department,pHD,MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

pingli wang, phD

Role: PRINCIPAL_INVESTIGATOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Site Status: RECRUITING

Countries

China

Central Contacts

pingli wang, phD

Role: CONTACT

pingliwang@zju.edu.cn

(0571)87783520

Facility Contacts

Pingli Wang, M.D

Role: primary

pingliwang@zju.edu.cn

+86 135 1680 8409

Other Identifiers

Reboot-105

Identifier Type: -

Identifier Source: org_study_id